Volume 27, Number 9—September 2021
Synopsis
Epidemiology, Clinical Features, and Outcomes of Coccidioidomycosis, Utah, 2006–2015
Table 1
Demographic and clinical data from coccidioidomycosis cases identified in the Intermountain Healthcare system, Utah, USA, 2006–2015*
Variables | No. (%) |
---|---|
Total patients |
364 |
Demographics | |
Age, y, median (IQR) | 61 (44–72) |
Pediatric <18 y | 13 (3.6) |
Male sex |
201 (55.2) |
Race | |
American Indian | 5 (1.4) |
Asian | 2 (0.5) |
Black | 1 (0.3) |
Hispanic | 20 (5.5) |
Pacific Islander | 9 (2.5) |
Unknown | 7 (1.9) |
White |
320 (87.9) |
Coexisting conditions/medical factors | |
Charlson comorbidity score, median (IQR) | 2 (0–4) |
Diabetes mellitus | 81 (22.3) |
Hepatic disease | 61 (16.8) |
Chronic pulmonary disease | 144 (39.6) |
Connective tissue disease | 27 (7.4) |
Congestive heart failure | 53 (14.6) |
Neurologic disease | 52 (14.3) |
Renal disease | 45 (12.4) |
History of malignancy | 76 (20.9) |
Hematopoietic stem cell transplant | 2 (0.5) |
Solid organ transplant | 2 (0.5) |
Any immunosuppressive medication | 27 (7.4) |
Corticosteroids | 25 (6.9) |
Anti-TNF | 3 (0.8) |
Antimetabolite | 2 (0.5) |
Chemotherapy |
4 (1.1) |
Laboratory test results | |
Lymphopenia, absolute lymphocyte count <500 | 12 (3.3) |
Lymphopenia value at diagnosis, absolute lymphocyte count, median (IQR) |
300 (300–400) |
Outcomes | |
Coccidioidomycosis-related hospital admission | 154 (42.3) |
Hospital length of stay, d, median (IQR) | 0 (0–5) |
42-d all-cause mortality | 20 (5.5) |
1-y all-cause mortality |
33 (9.1) |
Case classification | |
Proven | 192 (52.7) |
Probable | 172 (47.3) |
*Values are no. (%) except as indicated. IQR, interquartile range; TNF, tumor necrosis factor.